Introduction Outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in patients with pre-existing idiopathic pulmonary fibrosis (IPF) remain …

Background There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2)(COVID-19) infection in patients with idiopathic pulmonary fibrosis (IPF). The …

The pandemic of coronavirus disease 2019 (COVID-19), caused by a novel severe acute
respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has caused an enormous …

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …

Background Pulmonary fibrosis is associated with significant morbidity. Data are scarce on
the link between coronavirus disease (COVID-19) and pulmonary fibrosis. We aimed to …

Background Few is known about the long-term pulmonary sequelae after COVID-19
infection. Hence, the aim of this study is to characterize patients with persisting pulmonary …

Patients with preexisting interstitial lung disease (ILD) may be at high risk for severe
coronavirus disease (COVID-19) because of impaired lung function, propensity to develop …

Idiopathic pulmonary fibrosis (IPF) is considered the paradigmatic example of chronic
progressive fibrosing disease; IPF does not result from a primary immunopathogenic …

Patients with coronavirus disease 2019 (COVID-19) usually suffer from post-acute sequelae
of coronavirus disease 2019 (PASC). Pulmonary fibrosis (PF) has the most significant long …

Abstract Coronavirus disease 2019 (COVID-19) has become a major health burden
worldwide, with over 450 million confirmed cases and 6 million deaths. Although the acute …